Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors
The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivi...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2018-10, Vol.38 (10), p.5991-5998 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5998 |
|---|---|
| container_issue | 10 |
| container_start_page | 5991 |
| container_title | Anticancer research |
| container_volume | 38 |
| creator | Kafadar, Didem Yaylim, Ilhan Kafadar, Ali Metin Cacina, Canan Ergen, Arzu Kaynar, Mehmet Yasar Isbir, Turgay |
| description | The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivin gene polymorphism associates with benign and malignant brain tumors and whether it affects survivin serum levels.
Survivin polymorphism -31C>G was genotyped in 82 patients with brain tumors and 65 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and survivin levels were evaluated by enzyme-linked immuno sorbent assay (ELISA) in patients and controls.
Serum survivin levels in patients with malignant tumors were higher than patients with benign tumors (pG did not differ between patients and controls.
Survivin promoter -31C>G gene polymorphism seems to be associated with serum survivin levels in brain tumors of different grades and histologies. |
| doi_str_mv | 10.21873/anticanres.12947 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2115750512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2137114484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-89ba83474013c9047821bcc0a8999c26a533ea823bdea243d219bbc5c28fb3053</originalsourceid><addsrcrecordid>eNpdkU9LAzEQxYMotlY_gBcJePGyNX82TXLUorVQsNB6XrLZ1KbsZmuyu9Jvb2irBU8zDL_3mJkHwC1GQ4IFp4_KNVYr500YYiJTfgb6mEuccEbROegjwlDCEWI9cBXCBqHRSAp6CXoUEc4IRX2gp64zobGfqrG1g_UKLlrf2c46ODHOwHld7qrab9c2VFC5Ai6Mb6sTNDOdKQOM3Tw6GNcE-G2bNXz2Ks6WbdSGa3CxUmUwN8c6AB-vL8vxWzJ7n0zHT7NEU06aRMhcCZryFGGqJUq5IDjXGikhpdRkpBilRglC88IoktKCYJnnmmkiVjlFjA7Aw8F36-uvNl6VVTZoU5bKmboNGcGYcYYYJhG9_4du6ta7uF2kKMc4TUUaKXygtK9D8GaVbb2tlN9lGGX7BLJTAtk-gai5Ozq3eWWKP8Xvy-kPIHqEOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137114484</pqid></control><display><type>article</type><title>Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kafadar, Didem ; Yaylim, Ilhan ; Kafadar, Ali Metin ; Cacina, Canan ; Ergen, Arzu ; Kaynar, Mehmet Yasar ; Isbir, Turgay</creator><creatorcontrib>Kafadar, Didem ; Yaylim, Ilhan ; Kafadar, Ali Metin ; Cacina, Canan ; Ergen, Arzu ; Kaynar, Mehmet Yasar ; Isbir, Turgay</creatorcontrib><description>The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivin gene polymorphism associates with benign and malignant brain tumors and whether it affects survivin serum levels.
Survivin polymorphism -31C>G was genotyped in 82 patients with brain tumors and 65 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and survivin levels were evaluated by enzyme-linked immuno sorbent assay (ELISA) in patients and controls.
Serum survivin levels in patients with malignant tumors were higher than patients with benign tumors (p<0.001). Survivin levels in patients with malignant glial tumors and the frequency of the GG genotype were higher than in patients with benign tumors (p=0.04) and controls (p=0.05). The prevelance of the survivin gene promoter polymorphism -31C>G did not differ between patients and controls.
Survivin promoter -31C>G gene polymorphism seems to be associated with serum survivin levels in brain tumors of different grades and histologies.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12947</identifier><identifier>PMID: 30275230</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Apoptosis ; Benign ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Brain ; Brain cancer ; Brain Neoplasms - blood ; Brain Neoplasms - genetics ; Brain Neoplasms - pathology ; Brain tumors ; Case-Control Studies ; Enzyme-linked immunosorbent assay ; Female ; Follow-Up Studies ; Gene expression ; Gene polymorphism ; Genetic Predisposition to Disease ; Glioma ; Humans ; Inhibitor of Apoptosis Proteins - blood ; Inhibitor of Apoptosis Proteins - genetics ; Male ; Middle Aged ; Overexpression ; Patients ; Polymerase chain reaction ; Polymorphism ; Polymorphism, Single Nucleotide ; Prognosis ; Proteins ; Restriction fragment length polymorphism ; Serum levels ; Single-nucleotide polymorphism ; Survivin ; Tumors</subject><ispartof>Anticancer research, 2018-10, Vol.38 (10), p.5991-5998</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Oct 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-89ba83474013c9047821bcc0a8999c26a533ea823bdea243d219bbc5c28fb3053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30275230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kafadar, Didem</creatorcontrib><creatorcontrib>Yaylim, Ilhan</creatorcontrib><creatorcontrib>Kafadar, Ali Metin</creatorcontrib><creatorcontrib>Cacina, Canan</creatorcontrib><creatorcontrib>Ergen, Arzu</creatorcontrib><creatorcontrib>Kaynar, Mehmet Yasar</creatorcontrib><creatorcontrib>Isbir, Turgay</creatorcontrib><title>Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivin gene polymorphism associates with benign and malignant brain tumors and whether it affects survivin serum levels.
Survivin polymorphism -31C>G was genotyped in 82 patients with brain tumors and 65 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and survivin levels were evaluated by enzyme-linked immuno sorbent assay (ELISA) in patients and controls.
Serum survivin levels in patients with malignant tumors were higher than patients with benign tumors (p<0.001). Survivin levels in patients with malignant glial tumors and the frequency of the GG genotype were higher than in patients with benign tumors (p=0.04) and controls (p=0.05). The prevelance of the survivin gene promoter polymorphism -31C>G did not differ between patients and controls.
Survivin promoter -31C>G gene polymorphism seems to be associated with serum survivin levels in brain tumors of different grades and histologies.</description><subject>Apoptosis</subject><subject>Benign</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Brain</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - blood</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain tumors</subject><subject>Case-Control Studies</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene expression</subject><subject>Gene polymorphism</subject><subject>Genetic Predisposition to Disease</subject><subject>Glioma</subject><subject>Humans</subject><subject>Inhibitor of Apoptosis Proteins - blood</subject><subject>Inhibitor of Apoptosis Proteins - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Overexpression</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Restriction fragment length polymorphism</subject><subject>Serum levels</subject><subject>Single-nucleotide polymorphism</subject><subject>Survivin</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9LAzEQxYMotlY_gBcJePGyNX82TXLUorVQsNB6XrLZ1KbsZmuyu9Jvb2irBU8zDL_3mJkHwC1GQ4IFp4_KNVYr500YYiJTfgb6mEuccEbROegjwlDCEWI9cBXCBqHRSAp6CXoUEc4IRX2gp64zobGfqrG1g_UKLlrf2c46ODHOwHld7qrab9c2VFC5Ai6Mb6sTNDOdKQOM3Tw6GNcE-G2bNXz2Ks6WbdSGa3CxUmUwN8c6AB-vL8vxWzJ7n0zHT7NEU06aRMhcCZryFGGqJUq5IDjXGikhpdRkpBilRglC88IoktKCYJnnmmkiVjlFjA7Aw8F36-uvNl6VVTZoU5bKmboNGcGYcYYYJhG9_4du6ta7uF2kKMc4TUUaKXygtK9D8GaVbb2tlN9lGGX7BLJTAtk-gai5Ozq3eWWKP8Xvy-kPIHqEOg</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Kafadar, Didem</creator><creator>Yaylim, Ilhan</creator><creator>Kafadar, Ali Metin</creator><creator>Cacina, Canan</creator><creator>Ergen, Arzu</creator><creator>Kaynar, Mehmet Yasar</creator><creator>Isbir, Turgay</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors</title><author>Kafadar, Didem ; Yaylim, Ilhan ; Kafadar, Ali Metin ; Cacina, Canan ; Ergen, Arzu ; Kaynar, Mehmet Yasar ; Isbir, Turgay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-89ba83474013c9047821bcc0a8999c26a533ea823bdea243d219bbc5c28fb3053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Apoptosis</topic><topic>Benign</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Brain</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - blood</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain tumors</topic><topic>Case-Control Studies</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene expression</topic><topic>Gene polymorphism</topic><topic>Genetic Predisposition to Disease</topic><topic>Glioma</topic><topic>Humans</topic><topic>Inhibitor of Apoptosis Proteins - blood</topic><topic>Inhibitor of Apoptosis Proteins - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Overexpression</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Restriction fragment length polymorphism</topic><topic>Serum levels</topic><topic>Single-nucleotide polymorphism</topic><topic>Survivin</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kafadar, Didem</creatorcontrib><creatorcontrib>Yaylim, Ilhan</creatorcontrib><creatorcontrib>Kafadar, Ali Metin</creatorcontrib><creatorcontrib>Cacina, Canan</creatorcontrib><creatorcontrib>Ergen, Arzu</creatorcontrib><creatorcontrib>Kaynar, Mehmet Yasar</creatorcontrib><creatorcontrib>Isbir, Turgay</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kafadar, Didem</au><au>Yaylim, Ilhan</au><au>Kafadar, Ali Metin</au><au>Cacina, Canan</au><au>Ergen, Arzu</au><au>Kaynar, Mehmet Yasar</au><au>Isbir, Turgay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-10</date><risdate>2018</risdate><volume>38</volume><issue>10</issue><spage>5991</spage><epage>5998</epage><pages>5991-5998</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The single nucleotide polymorphism -31C/G identified in the survivin gene promoter seems to be associated with over-expression of survivin, an anti-apoptotic protein. In gliomas, increased survivin expression correlated with decreased survival. The aim of the study was to investigate whether survivin gene polymorphism associates with benign and malignant brain tumors and whether it affects survivin serum levels.
Survivin polymorphism -31C>G was genotyped in 82 patients with brain tumors and 65 healthy controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and survivin levels were evaluated by enzyme-linked immuno sorbent assay (ELISA) in patients and controls.
Serum survivin levels in patients with malignant tumors were higher than patients with benign tumors (p<0.001). Survivin levels in patients with malignant glial tumors and the frequency of the GG genotype were higher than in patients with benign tumors (p=0.04) and controls (p=0.05). The prevelance of the survivin gene promoter polymorphism -31C>G did not differ between patients and controls.
Survivin promoter -31C>G gene polymorphism seems to be associated with serum survivin levels in brain tumors of different grades and histologies.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>30275230</pmid><doi>10.21873/anticanres.12947</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2018-10, Vol.38 (10), p.5991-5998 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2115750512 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Apoptosis Benign Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Brain Brain cancer Brain Neoplasms - blood Brain Neoplasms - genetics Brain Neoplasms - pathology Brain tumors Case-Control Studies Enzyme-linked immunosorbent assay Female Follow-Up Studies Gene expression Gene polymorphism Genetic Predisposition to Disease Glioma Humans Inhibitor of Apoptosis Proteins - blood Inhibitor of Apoptosis Proteins - genetics Male Middle Aged Overexpression Patients Polymerase chain reaction Polymorphism Polymorphism, Single Nucleotide Prognosis Proteins Restriction fragment length polymorphism Serum levels Single-nucleotide polymorphism Survivin Tumors |
| title | Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T04%3A46%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigation%20of%20Survivin%20Gene%20Polymorphism%20and%20Serum%20Survivin%20Levels%20in%20Patients%20with%20Brain%20Tumors&rft.jtitle=Anticancer%20research&rft.au=Kafadar,%20Didem&rft.date=2018-10&rft.volume=38&rft.issue=10&rft.spage=5991&rft.epage=5998&rft.pages=5991-5998&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12947&rft_dat=%3Cproquest_cross%3E2137114484%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2137114484&rft_id=info:pmid/30275230&rfr_iscdi=true |